In the second quarter of 2006, we filed an Investigational New Drug application (IND) for SEP-227162, a serotonin and norepinephrine reuptake inhibitor (SNRI) for the treatment of depression and/or anxiety. In early 2007, we began a Phase I study of SEP-227162, and Sepracor currently expects to initiate a Phase II Study of SEP-227162 in the second quarter of 2008.

Depression
Depression is a serious medical condition. According to the National Institute of Mental Health, symptoms of depression include sad mood, loss of interest or pleasure in activities that were once enjoyed, change in appetite or weight, difficulty sleeping or oversleeping, physical slowing or agitation, energy loss, feelings of worthlessness or inappropriate guilt, difficulty thinking or concentrating, and recurrent thoughts of death or suicide.